Cogent Biosciences closed at $31.49 on Nov 4, up 1.38%, 26.5% below its 52-week closing high. Volume of 2.2M shares was 1.01× its 20-day average (close to normal).
Split-adjusted performance: +3.7% over one month, -12.2% over six months, +103.2% over one year.
Short interest was 19.7M shares at the Oct 15 settlement, up 1.0% from the prior report (13.2% of float, 8.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| COGTCogent Biosciences | $31.49 | +1.38% | −12.2% | — | — | — | $5.46B | |
| MANEVeradermics, Incorporated | $136.51 | +2.17% | +24.4% | — | — | — | $5.70B | Compare |
| ERASErasca | $14.91 | +1.84% | +36.8% | — | — | — | $5.21B | Compare |
| PTCTPTC Therapeutics | $68.97 | +1.25% | +3.6% | +69.6% | −14.4% | — | $5.76B | Compare |
| TVTXTravere Therapeutics | $52.42 | +6.09% | +17.1% | +36.2% | −23.3% | — | $4.94B | Compare |
| DNTHDianthus Therapeutics | $85.81 | +3.76% | −5.1% | +294.3% | −6598.6% | — | $4.80B | Compare |
| MIRMMirum Pharmaceuticals | $96.97 | +11.42% | −11.9% | +39.6% | −22.0% | — | $6.30B | Compare |
| LGNDLigand Pharmaceuticals | $316.13 | +0.83% | +35.9% | −31.8% | −36.2% | 122.9 | $6.32B | Compare |
| IONSIonis Pharmaceuticals | $40.15 | −0.67% | −47.8% | −40.7% | −42.8% | — | $6.67B | Compare |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
